WO2002070517A2 - Inhibiteurs de cysteine protease de type cathepsine - Google Patents

Inhibiteurs de cysteine protease de type cathepsine Download PDF

Info

Publication number
WO2002070517A2
WO2002070517A2 PCT/CA2002/000258 CA0200258W WO02070517A2 WO 2002070517 A2 WO2002070517 A2 WO 2002070517A2 CA 0200258 W CA0200258 W CA 0200258W WO 02070517 A2 WO02070517 A2 WO 02070517A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
halo
optionally substituted
heteroaryl
cycloalkyl
Prior art date
Application number
PCT/CA2002/000258
Other languages
English (en)
Other versions
WO2002070517A3 (fr
Inventor
Renata Marcella Oballa
Original Assignee
Merck Frosst Canada & Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada & Co. filed Critical Merck Frosst Canada & Co.
Priority to AU2002242500A priority Critical patent/AU2002242500A1/en
Publication of WO2002070517A2 publication Critical patent/WO2002070517A2/fr
Publication of WO2002070517A3 publication Critical patent/WO2002070517A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Definitions

  • disorders in humans and other mammals involve or are associated with abnormal bone resorption.
  • disorders include, but are not limited to, osteoporosis, glucocorticoid induced osteoporosis, Paget's disease, abnormally increased bone turnover, periodontal disease, tooth loss, bone fractures, rheumatoid arthritis, osteoarthritis, periprosthetic osteolysis, osteogenesis imperfecta, metastatic bone disease, hypercalcemia of malignancy, and multiple myeloma.
  • osteoporosis which in its most frequent manifestation occurs in postmenopausal women.
  • Osteoporosis is a systemic skeletal disease characterized by a low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture. Osteoporotic fractures are a major cause of morbidity and mortality in the elderly population. As many as 50% of women and a third of men will experience an osteoporotic fracture. A large segment of the older population already has low bone density and a high risk of fractures. There is a significant need to both prevent and treat osteoporosis and other conditions associated with bone resorption. Because osteoporosis, as well as other disorders associated with bone loss, are generally chronic conditions, it is believed that appropriate therapy will typically require chronic treatment.
  • Osteoporosis is characterized by progressive loss of bone architecture and mineralization leading to the loss in bone strength and an increased fracture rate.
  • the skeleton is constantly being remodeled by a balance between osteoblasts that lay down new bone and osteoclasts that breakdown, or resorb, bone. In some disease conditions and advancing age the balance between bone formation and resorption is disrupted; bone is removed at a faster rate. Such a prolonged imbalance of resorption over formation leads to weaker bone structure and a higher risk of fractures.
  • Bone resorption is primarily performed by osteoclasts, which are multinuclear giant cells. Osteoclasts resorb bone by forming an initial cellular attachment to bone tissue, followed by the formation of an extracellular compartment or lacunae.
  • the lacunae are maintained at a low pH by a proton-ATP pump.
  • the acidified environment in the lacunae allows for initial demineralization of bone followed by the degradation of bone proteins or collagen by proteases such as cysteine proteases.
  • proteases such as cysteine proteases. See Delaisse, J. M. et al, 1980, Biochem J 192:365-368; Delaisse, J. et al., 1984, Biochem Biophys Res Commun :441-447; Delaisse, J. M. et /.,1987, Bone 8 ⁇ 305-313, which are hereby incorporated by reference in their entirety.
  • Collagen constitutes 95 % of the organic matrix of bone. Therefore, proteases involved in collagen degradation are an essential component of bone turnover, and as a consequence, the development and progression of osteoporosis.
  • Cathepsins belong to the papain superfamily of cysteine proteases. These proteases function in the normal physiological as well as pathological degradation of connective tissue. Cathepsins play a major role in intracellular protein degradation and turnover and remodeling. To date, a number of cathepsin have been identified and sequenced from a number of sources. These cathepsins are naturally found in a wide variety of tissues. For example, cathepsin B, F, H, L, K, S, W, and Z have been cloned. Cathepsin K (which is also known by the abbreviation cat K) is also known as cathepsin O and cathepsin O2.
  • Cathepsin L is implicated in normal lysosomal proteolysis as well as several disease states, including, but not limited to, metastasis of melanomas.
  • Cathepsin S is implicated in Alzheimer's disease and certain autoimmune disorders, including, but not limited to juvenile onset diabetes, multiple sclerosis, pemphigus vulgaris, Graves' disease, myasthenia gravis, systemic lupus erythemotasus, rheumatoid arthritis and Hashimoto's thyroiditis; allergic disorders, including, but not limited to asthma; and allogenic immunbe responses, including, but not limited to, rejection of organ transplants or tissue grafts. Increased Cathepsin B levels and redistribution of the enzyme are found in tumors, suggesting a role in tumor invasion and matastasis.
  • Cathpsin B activity is implicated in such disease states as rheumatoid arthritis, osteoarthritis, pneumocystisis carinii, acute pancreatitis, inflammatory airway disease and bone and joint disorders.
  • Cysteine protease inhibitors such as E-64 (tr ⁇ ws-epoxysuccinyl-L- leucylamide-(4-guanidino) butane) are known to be effective in inhibiting bone resorption. See Delaisse, J. M. et al., 1987, Bone 8:305-313, which is hereby incorporated by reference in its entirety. Recently, cathepsin K was cloned and found specifically expressed in osteoclasts See Tezuka, K. et al., 1994, J Biol Chem 269:1106-1109; Shi, G. P. et al.,1995, FEBS Lett 357: 129-134; Bromme, D.
  • Cathepsin K is synthesized as a 37 kDa pre-pro enzyme, which is localized to the lysosomal compartment and where it is presumably autoactivated to the mature 27 kDa enzyme at low pH. See McQueney, M. S. et al, 1997, J Biol Chem 272:13955-13960; Littlewood-Evans, A. et al, 1997, Bone 20:81-86, which are hereby incorporated by reference in their entirety. Cathepsin K is most closely related to cathepsin S having 56 % sequence identity at the amino acid level.
  • the S 2 P 2 substrate specificity of cathepsin K is similar to that of cathepsin S with a preference in the PI and P2 positions for a positively charged residue such as arginine, and a hydrophobic residue such as phenylalanine or leucine, respectively. See Bromme, D. et al, 1996, J Biol Chem 271: 2126-2132; Bossard, M. J. et al, 1996, J Biol Chem 271:12517-12524, which are hereby incorporated by reference in their entirety.
  • Cathepsin K is active at a broad pH range with significant activity between pH 4-8, thus allowing for good catalytic activity in the resorption lacunae of osteoclasts where the pH is about 4-5.
  • Compounds of the instant invention are useful as inhibitors of cathepsins. Particularly, the compounds of the instant invention are useful as inhibitors of Cathepsins K, L, S and/or B. More particularly, the compounds of the instant invention are useful as inhibitors of Cathepsins K and/or L.
  • the present invention relates to compounds of the following chemical formula:
  • Rl and R2 are e independently selected from the group consisting of hydrogen and Ci-6 alkyl; or Rl and R2 can be taken together with the carbon atom to which they are attached to form a C3-8 cycloalkyl ring wherein said 3-8 membered ring system may be optionally substituted with Ci- alkyl and halo;
  • X is selected from the group consisting of NH, NR4, -NHSO2-, -SO2NH-, O, - C(R5)(R6)0-, -0C(R5)(R6)-, S, SO2, -C(R5)(R6)S-, -SC(R5)(R6)-, C(R5)(R6)SO2, S ⁇ 2C(R5)(R6)-, -C(R5)(R6)-, -C(R5)(R6)N(R5)(R6)., -N(R5)(R6)C(R5)(R6).
  • R4 is C 1-6 alkyl; or R4 and R2 can be taken together with any of the atoms to which they may be attached or are between them to form a 4-8 membered ring system wherein said 4-8 membered ring system may be optionally substituted with Ci -6 alkyl and halo;
  • R5 and R6 are each independently selected from the group consisting of hydrogen and Ci -6 alkyl, wherein said alkyl group can be optionally substituted with one to three halo;
  • D and E are each independently selected from optionally substituted aryl, heteroaryl,
  • R3 is selected from the group consisting of hydrogen, C ⁇ _6 alkyl, halo, aryl, heteroaryl, Ci -6 cycloalkyl and heterocycloalkyl, wherein said alkyl, aryl, heteroaryl,
  • Ci-6 cycloalkyl and heterocycloalkyl can be optionally substituted with Ci -6 alkyl and halo; m is independently selected from an integer from one to five; n is independently selected from an integer from zero to two;
  • A is selected from the group consisting optionally substituted aryl and heteroaryl; and the pharmaceutically acceptable salts and N-oxide derivatives thereof.
  • the present invention also relates to pharmaceutical compositions comprising the compounds of the present invention and a pharmaceutically acceptable carrier.
  • the present invention also relates to methods for making the pharmaceutical compositions of the present invention.
  • the present invention also relates to methods of inhibiting cathepsin activity and/or treating cathepsin dependent conditions in a mammal in need thereof comprising administering to the mammal the compounds and pharmaceutical compositions of the present invention.
  • the present invention also relates to methods of treating, preventing and/or reducing bone loss in a mammal in need thereof comprising administering to the mammal the compounds and pharmaceutical compositions of the present invention.
  • the present invention also relates to methods of inhibiting treating and/or preventing osteoporosis in a mammal in need thereof comprising administering to the mammal the compounds and pharmaceutical compositions of the present invention.
  • the present invention also relates to methods of reducing bone loss in a mammal in need thereof comprising administering to the mammal the compounds and pharmaceutical compositions of the present invention.
  • the present invention also relates to methods of treating and/or preventing bone fractures in a mammal in need thereof comprising administering to the mammal the compounds and pharmaceutical compositions of the present invention.
  • the present invention relates to the use of the compounds and pharmaceutical compositions of the present invention for the preparation of a medicament for treating or preventing bone loss in a mammal in need thereof.
  • the present invention relates to pharmaceutical compositions useful for treating or preventing bone loss in a mammal comprising a pharmaceutically effective amount of compounds of the present invention in association with pharmaceutically acceptable carriers.
  • the present invention relates to compounds of the following chemical formula:
  • Rl and R are each independently selected from the group consisting of hydrogen and C ⁇ - alkyl; or Rl and R2 can be taken together with the carbon atom to which they are attached to form a C3-8 cycloalkyl ring wherein said 3-8 membered ring system may be optionally substituted with C1 -6 alkyl and halo;
  • X is selected from the group consisting of NH, NR4, -NHSO2-, -SO2NH-, O, - C(R5)(R6)0-, -0C(R5)(R6)-, S, SO2, -C(R5)(R6)S-, -SC(R5)(R6)., C(R5)(R6)SO2, S ⁇ 2C(R5)(R6)-, -C(R5)(R6)-, -C(R5)(R6)N(R5)(R6)., -N(R5)(R6)C(R6). ;
  • R4 is CI-6 alkyl; or R4 and R2 can be taken together with any of the atoms to which they may be attached or are between them to form a 4-8 membered ring system wherein said 4-8 membered ring system may be optionally substituted with Ci-6 alkyl and halo;
  • R5 and R6 are each independently selected from the group consisting of hydrogen and Ci- alkyl, wherein said alkyl group can be optionally substituted with one to three halo;
  • D and E are each independently selected from optionally substituted aryl, heteroaryl, Ci-6 cycloalkyl and heterocycloalkyl wherein said aryl, heteroaryl, cycloalkyl and heterocycloalkyl may be optionally substituted with C ⁇ _6 alkyl and halo;
  • R3 is selected from the group consisting of hydrogen, Ci-6 alkyl, halo, aryl, heteroaryl, Ci- cycloalkyl and heterocycloalkyl, wherein said alkyl, aryl, heteroaryl,
  • Cl-6 cycloalkyl and heterocycloalkyl can be optionally substituted with Ci- alkyl and halo; m is independently selected from an integer from one to five; n is independently selected from an integer from zero to two;
  • A is selected from the group consisting optionally substituted aryl and heteroaryl; and the pharmaceutically acceptable salts and N-oxide derivatives thereof.
  • A is represented as
  • R7 , R8 and R9 are each independently selected from the group consisting of hydrogen, Cl-6 alkyl, Ci-6 alkoxy, aryl-Ci-6 alkoxy, Ci- cycloalkoxy, Ci-6 cycloalkyl-Ci-6 alkoxy, heterocyclyoxy, heterocyclyl-C -6 alkoxy, amino-Ci-6 alkoxy and halo.
  • X is NR4 ; and R4 and R2 are taken together with any of the atoms to which they may be attached or are between them to form a 4-8 membered ring system wherein said 4-8 membered ring system may be optionally substituted with Ci-6 alkyl and halo.
  • X is NH.
  • X is S.
  • D is selected from an optionally substituted 5-membered ring heteroaryl wherein said heteroaryl can be substituted with Ci-6 alkyl, halo.
  • the present invention relates to compounds of the formula:
  • X is selected from the group consisting of NH, NR4, -NHSO2-, -SO2NH-, O, - C(R5)(R6) ⁇ -, -0C(R5)(R6)-, S, SO2, -C(R5)(R6)S-, -SC(R5)(R6)-, C(R5)(R6)SO2, S ⁇ 2C(R5)(R6)-, -C(R5)(R6)-, -C(R5)(R6)N(R5)(R6)-, -N(R5)(R6)C(R5)(R6)- ; R 1S Cl-6 alkyl; or R4 and R2 can be taken together with any of the atoms to which they may be attached or are between them to form a 4-8 membered ⁇ ng system wherein said 4-8 membered ⁇ ng system may be optionally substituted with Cl-6 alkyl and halo; R5 and R6 are each independently selected from the group consisting of hydrogen and Ci-6 alkyl, wherein
  • D and E are each independently selected from optionally substituted aryl, heteroaryl, Ci-6 cycloalkyl and heterocycloalkyl wherein said aryl, heteroaryl, cycloalkyl and heterocycloalkyl may be optionally substituted with Ci-6 alkyl and halo;
  • R3 IS selected from the group consisting of hydrogen, Ci-6 alkyl, halo, aryl, heteroaryl, Ci-6 cycloalkyl and heterocycloalkyl, wherein said alkyl, aryl, heteroaryl, Ci-6 cycloalkyl and heterocycloalkyl can be optionally substituted with Ci-6 alkyl and halo;
  • Ra is selected from hydrogen, Ci-6 alkyl and halo;
  • m is independently selected from an integer from one to five, n is independently selected from an integer from one to five;
  • A is selected from the group consisting optionally substituted aryl and heteroaryl; and the pharmaceutically acceptable salts and N-oxide de ⁇ vatives thereof.
  • Specific embodiments of the present invention mlcude, but are not limited to (2S)-N- ⁇ 2-[4-(benzyloxy)an ⁇ l ⁇ no]ethyl ⁇ -4-methyl-2-( ⁇ 4-[4-(l- p ⁇ peraz ⁇ nyl)phenyl]-3-th ⁇ enyl ⁇ am ⁇ no)pentanam ⁇ de and the pharmaceutically acceptable salts thereof.
  • An embodiment of the invention is a method of inhibiting cathepsin activity in a mammal in need thereof, comp ⁇ sing adm iste ⁇ ng to the mammal a therapeutically effective amount of any of the compounds or any of the pharmaceutical compositions described above.
  • a class of the embodiment is the method wherein the cathepsin activity is cathepsin K activity.
  • Another embodiment of the invention is a method of treating or preventing cathepsin dependent conditions in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of any of the compounds or any of the pharmaceutical compositions described above.
  • a class of the embodiment is the method wherein the cathepsin activity is cathepsin K activity.
  • Another embodiment of the invention is a method of treating or preventing bone loss in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of any of the compounds or any of the pharmaceutical compositions described above.
  • Another embodiment of the invention is a method of reducing bone loss in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of any of the compounds or any of the pharmaceutical compositions described above.
  • Another embodiment of the invention is a method of treating or preventing bone fractures in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of any of the compounds or any of the pharmaceutical compositions described above.
  • Another embodiment of the invention is a method of treating or preventing osteoporosis in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of any of the compounds or any of the above pharmaceutical compositions described above.
  • Exemplifying the invention is a pharmaceutical composition comprising any of the compounds described above and a pharmaceutically acceptable carrier. Also exemplifying the invention is a pharmaceutical composition made by combining any of the compounds described above and a pharmaceutically acceptable carrier. An illustration of the invention is a process for making a pharmaceutical composition comprising combining any of the compounds described above and a pharmaceutically acceptable carrier.
  • the invention is the use of any of the compounds described above in the preparation of a medicament for the treatment and/or prevention of osteoporosis in a mammal in need thereof. Still further exemplifying the invention is the use of any of the compounds described above in the preparation of a medicament for the treatment and/or prevention of: bone loss, bone resorption, bone fractures, and/or disorders related to cathepsin functioning.
  • the present invention is also directed to combinations of any of the compounds or any of the pharmaceutical compositions described above with one or more agents useful in the prevention or treatment of osteoporosis.
  • the compounds of the instant invention may be effectively administered in combination with effective amounts of other agents such as an organic bisphosphonate or an estrogen receptor modulator.
  • Nonlimiting examples of said organic bisphosphonates include alendronate, clodronate, etidronate, ibandronate, incadronate, minodronate, neridronate, risedronate, piridronate, pamidronate, tiludronate, zoledronate, pharmaceutically acceptable salts or esters thereof, and mixtures thereof.
  • Preferred organic bisphosphonates include alendronate and pharmaceutically acceptable salts and mixtures thereof. Most preferred is alendronate monosodium trihydrate.
  • the precise dosage of the bisphosphonate will vary with the dosing schedule, the oral potency of the particular bisphosphonate chosen, the age, size, sex and condition of the mammal or human, the nature and severity of the disorder to be treated, and other relevant medical and physical factors. Thus, a precise pharmaceutically effective amount cannot be specified in advance and can be readily determined by the caregiver or clinician. Appropriate amounts can be determined by routine experimentation from animal models and human clinical studies. Generally, an appropriate amount of bisphosphonate is chosen to obtain a bone resorption inhibiting effect, i.e. a bone resorption inhibiting amount of the bisphosphonate is administered. For humans, an effective oral dose of bisphosphonate is typically from about 1.5 to about 6000 ⁇ g/kg body weight and preferably about 10 to about 2000 ⁇ g/kg of body weight.
  • a unit dosage typically comprises from about 8.75 mg to about 140 mg of the alendronate compound, on an alendronic acid active weight basis, i.e. on the basis of the corresponding acid.
  • salts of the compounds of this invention refer to non-toxic “pharmaceutically acceptable salts.”
  • Other salts may, however, be useful in the preparation of the compounds according to the invention or of their pharmaceutically acceptable salts.
  • salts encompassed within the term "pharmaceutically acceptable salts" refer to non-toxic salts which are generally prepared by reacting the free base with a suitable organic or inorganic acid.
  • Representative salts include the following: acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, N-methylglucamine ammonium salt, oleate, oxalate, pam
  • suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g., sodium or potassium salts; alkaline earth metal salts, e.g., calcium or magnesium salts; and salts formed with suitable organic ligands, e.g., quaternary ammonium salts.
  • alkali metal salts e.g., sodium or potassium salts
  • alkaline earth metal salts e.g., calcium or magnesium salts
  • suitable organic ligands e.g., quaternary ammonium salts.
  • the compounds of the present invention can have chiral centers and occur as racemates, racemic mixtures, diastereomeric mixtures, and as individual diastereomers, or enantiomers with all isomeric forms being included in the present invention. Therefore, where a compound is chiral, the separate enantiomers, substantially free of the other, are included within the scope of the invention; further included are all mixtures of the two enantiomers. Also included within the scope of the invention are polymorphs, hydrates and solvates of the compounds of the instant invention.
  • the present invention includes within its scope prodrugs of the compounds of this invention.
  • prodrugs will be functional derivatives of the compounds of this invention which are readily convertible in vivo into the required compound.
  • the term “administering” shall encompass the treatment of the various conditions described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound in vivo after administration to the patient.
  • Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs,” ed. H. Bundgaard, Elsevier, 1985, which is incorporated by reference herein in its entirety.
  • Metabolites of these compounds include active species produced upon introduction of compounds of this invention into the biological milieu.
  • the term "therapeutically effective amount” shall mean that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by a researcher or clinician.
  • bone resorption refers to the process by which osteoclasts degrade bone.
  • alkyl shall mean straight or branched chain alkanes of one to ten total carbon atoms, or any number within this range (i.e., methyl, ethyl, 1- propyl, 2-propyl, n-butyl, s-butyl, t-butyl, etc.).
  • cycloalkyl shall mean cyclic rings of alkanes of three to eight total carbon atoms, or any number within this range (i.e., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl).
  • heterocycloalkyl shall mean a 3- to 8- membered fully saturated heterocyclic ring containing one or two heteroatoms chosen from N, O or S. Examples of cycloheteroalkyl groups include, but are not limited to piperidinyl, pyrrolidinyl, azetidinyl, morpholinyl, piperazinyl.
  • aryl refers to a monocyclic or polycyclic system comprising at least one aromatic ring, wherein the monocylic or polycyclic system contains 0, 1, 2, 3, or 4 heteroatoms chosen from N, O, or S, and wherein the monocylic or polycylic system is either unsubstituted or substituted with one or more groups independently selected from hydrogen, halogen, Ci-io alkyl, C3-8 cycloalkyl, aryl, aryl Ci-8 alkyl, amino, amino Ci-8 alkyl, Ci-3 acylamino, Ci-3 acylamino C ⁇ _8 alkyl, Ci-6 alkylamino, Ci-6 alkylamino Ci-8 alkyl, Ci-6 dialkylamino, Ci-6 dialkylamino-Ci-8 alkyl, Ci-4 alkoxy, Ci-4 alkoxy Cl-6 alkyl, hydroxycarbonyl, hydroxycarbonyl Ci-6 alkyl, Ci-5 alkoxycarbonyl, C ⁇
  • aryl examples include, but are not limited to, phenyl, naphthyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinolinyl, isoquinolinyl, benzofuranyl, benzothienyl, imidazolyl, benzimidazolyl, indolyl, thienyl, furyl, dihydrobenzofuryl, benzo(l,3) dioxolane, oxazolyl, isoxazolyl and thiazolyl, isothiazolyl, pyrazolyl, pyrrolyl, tetrazolyl, triazolyl, oxadiazolyl, oxatriazolyl, thiadiazolyl, thiatriazolyl which are either unsubstituted or substituted with one or more groups independently selected from hydrogen, halogen, Ci-io alkyl, C3-8 cycloalky
  • the aryl group is unsubstituted, mono-, di-, tri- or tetra-substituted with one to four of the above-named substituents; more preferably, the aryl group is unsubstituted, mono-, di- or tri-substituted with one to three of the above-named substituents; most preferably, the aryl group is unsubstituted, mono- or di-substituted with one to two of the above- named substituents.
  • heteroaryl shall refer to a system that includes an aryl portion, where aryl is as defined above, and one or two heteroatoms chosen from N, O or S.
  • halo shall include iodo, bromo, chloro and fluoro.
  • alkyl or aryl or either of their prefix roots appear in a name of a substituent (e.g., aryl C ⁇ -8 alkyl) it shall be interpreted as including those limitations given above for "alkyl” and "aryl.”
  • Designated numbers of carbon atoms e.g., Ci-io shall refer independently to the number of carbon atoms in an alkyl or cyclic alkyl moiety or to the alkyl portion of a larger substituent in which alkyl appears as its prefix root.
  • Rl and R2 when on the same carbon atom, can be taken together with the carbon atom to which they are attached to form a 3-8 membered ring wherein said 3-8 membered ring system may be optionally substituted with C ⁇ _6 alkyl and halo.
  • R4 and R can be taken together with any of the atoms to which they may be attached or are between them to form a 4-8 membered ring system, wherein said 4-8 membered ring system may be optionally substituted with Cl-6 alkyl and halo.
  • the terminal portion of the designated side chain is described first, followed by the adjacent functionality toward the point of attachment.
  • a Ci-5 alkylcarbonylamino Ci-6 alkyl substituent is equivalent to O
  • the compounds of the present invention are available in racemic form or as individual enantiomers. It is generally preferable to administer the compounds of the present invention structure as enantiomerically pure formulations since most or all of the desired bioactivity resides with a single enantiomer. Racemic mixtures can be separated into their individual enantiomers by any of a number of conventional methods. These include chiral chromatography, derivatization with a chiral auxiliary followed by separation by chromatography or crystallization, and fractional crystallization of diastereomeric salts.
  • the compounds of the present invention can be used in combination with other agents useful for treating cathepsin-mediated conditions.
  • the individual components of such combinations can be administered separately at different times during the course of therapy or concurrently in divided or single combination forms.
  • the instant invention is therefore to be understood as embracing all such regimes of simultaneous or alternating treatment and the term "administering" is to be interpreted accordingly.
  • the scope of combinations of the compounds of this invention with other agents useful for treating estrogen-mediated conditions includes in principle any combination with any pharmaceutical composition useful for treating disorders related to estrogen functioning.
  • composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
  • the compounds of the present invention can be administered in such oral dosage forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixers, tinctures, suspensions, syrups and emulsions. Likewise, they may also be administered in intravenous (bolus or infusion), intraperitoneal, topical (e.g., ocular eyedrop), subcutaneous, intramuscular or transdermal (e.g., patch) form, all using forms well known to those of ordinary skill in the pharmaceutical arts.
  • the dosage regimen utilizing the compounds of the present invention is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt thereof employed.
  • An ordinarily skilled physician, veterinarian or clinician can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.
  • Oral dosages of the present invention when used for the indicated effects, will range between about 0.01 mg per kg of body weight per day (mg/kg/day) to about 100 mg/kg/day, preferably 0.01 to 10 mg/kg/day, and most preferably 0.1 to 5.0 mg/kg/day.
  • compositions are preferably provided in the form of tablets containing 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100 and 500 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated.
  • a medicament typically contains from about 0.01 mg to about 500 mg of the active ingredient, preferably, from about 1 mg to about 100 mg of active ingredient.
  • the most preferred doses will range from about 0.1 to about 10 mg/kg/minute during a constant rate infusion.
  • compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily.
  • preferred compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in the art.
  • the dosage administration will, of course, be continuous rather than intermittant throughout the dosage regimen.
  • the compounds herein described in detail can form the active ingredient, and are typically administered in admixture with suitable pharmaceutical diluents, excipients or carriers (collectively referred to herein as 'carrier' materials) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with conventional pharmaceutical practices.
  • suitable pharmaceutical diluents, excipients or carriers collectively referred to herein as 'carrier' materials
  • the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like; for oral administration in liquid form, the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture.
  • suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture.
  • Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like.
  • Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
  • Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.
  • the compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.
  • Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.
  • Compounds of the present invention may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled.
  • the compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers.
  • Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol, polyhydroxy-ethylaspartamide-phenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues.
  • the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polyactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and crosslinked or amphipathic block copolymers of hydrogels.
  • a drug for example, polylactic acid, polyglycolic acid, copolymers of polyactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and crosslinked or amphipathic block copolymers of hydrogels.
  • CC1 4 carbon tetrachloride
  • EDCI 1 -(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
  • HATU o-(7-azabenzotriazol- 1 -yl)-N,N,N' ,N' -tetramethyluronium hexafluorophosphate
  • KOBu' potassium tert-butoxide
  • LiOH lithium hydroxide
  • mCPBA metachloroperbenzoic acid
  • MeSO 3 H methane sulfonic acid
  • MgSO 4 magnesium sulfate
  • NaHCO 3 sodium hydrogencarbonate
  • Na 2 SO 4 sodium sulfate
  • PdCl 2 (dppf) [ 1 , 1 ' -bi s(diphenylphosphino)ferrocene]dichloropalladium(II)
  • PPTS pyridinium p-toluenesulfonate
  • tPr 2 Nli lithium diisopropyl amide
  • novel compounds of the present invention can be prepared according to the following general procedures using appropriate materials and are further exemplified by the following specific examples.
  • the compounds illustrated in the examples are not, however, to be construed as forming the only genus that is considered as the invention.
  • the following examples further illustrate details for the preparation of the compounds of the present invention. Those skilled in the art will readily understand that known variations of the conditions and processes of the following preparative procedures can be used to prepare these compounds. All temperatures are degrees Celsius unless otherwise noted.
  • Compounds of the present invention can be prepared according to Scheme 1, as indicated below.
  • the amine hydrochloride 1 can be coupled with the desired acid 2 to generate compound 3 of the present invention.
  • the preparation of the 2-aminoethyl anilines 1 is as described in the literature (J. Org. Chem. 1992, 57, 6257).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une nouvelle classe de composés qui sont des inhibiteurs de cystéine protéase, parmi lesquels, des inhibiteurs des cathepsines K, L, S et B. Ces composés sont utiles pour le traitement de maladies, telles que l'ostéoporose, pour lesquelles le blocage de la résorption osseuse est préconisé.
PCT/CA2002/000258 2001-03-02 2002-02-28 Inhibiteurs de cysteine protease de type cathepsine WO2002070517A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002242500A AU2002242500A1 (en) 2001-03-02 2002-02-28 Cathepsin cysteine protease inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27280001P 2001-03-02 2001-03-02
US60/272,800 2001-03-02

Publications (2)

Publication Number Publication Date
WO2002070517A2 true WO2002070517A2 (fr) 2002-09-12
WO2002070517A3 WO2002070517A3 (fr) 2003-01-16

Family

ID=23041336

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2002/000258 WO2002070517A2 (fr) 2001-03-02 2002-02-28 Inhibiteurs de cysteine protease de type cathepsine

Country Status (2)

Country Link
AU (1) AU2002242500A1 (fr)
WO (1) WO2002070517A2 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004112709A2 (fr) * 2003-06-13 2004-12-29 Irm Llc Inhibiteurs de cathepsine s
US7109243B2 (en) 2003-03-24 2006-09-19 Irm Llc Inhibitors of cathepsin S
JP2007502844A (ja) * 2003-08-20 2007-02-15 アイアールエム・リミテッド・ライアビリティ・カンパニー カテプシンｓの阻害剤
US7358373B2 (en) 2005-07-27 2008-04-15 Roche Palo Alto Llc Cathepsin K inhibitors
US7384970B2 (en) 2003-03-24 2008-06-10 Irm Llc Inhibitors of cathepsin S
WO2008147228A1 (fr) * 2007-05-31 2008-12-04 Fonterra Corporate Research And Development Limited Traitement ou prévention de maladies osseuses
WO2009125861A1 (fr) * 2008-04-09 2009-10-15 帝人ファーマ株式会社 Inhibiteur de cystéine protéase
WO2009128521A1 (fr) * 2008-04-15 2009-10-22 帝人ファーマ株式会社 Inhibiteur de cystéine protéase

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999040088A1 (fr) * 1998-02-09 1999-08-12 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines et guanidines utiles en tant qu'inhibiteurs de protease et plus particulierement en tant qu'inhibiteurs d'urokinase
WO2000048993A1 (fr) * 1999-02-16 2000-08-24 Novartis Ag Arylaminoalkylamides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999040088A1 (fr) * 1998-02-09 1999-08-12 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines et guanidines utiles en tant qu'inhibiteurs de protease et plus particulierement en tant qu'inhibiteurs d'urokinase
WO2000048993A1 (fr) * 1999-02-16 2000-08-24 Novartis Ag Arylaminoalkylamides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
E.N. HAMBARTSOUMIAN, A.S. VORSKANIAN, V.V. DOVLATIAN: "Synthesis and transformations of aminoethylamides of aryloxyacetic acids" ARMYANSKII KHIMICHESKII ZHURNAL, vol. 43, no. 9, 1990, pages 581-589, XP001119542 erewan *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109243B2 (en) 2003-03-24 2006-09-19 Irm Llc Inhibitors of cathepsin S
US7384970B2 (en) 2003-03-24 2008-06-10 Irm Llc Inhibitors of cathepsin S
WO2004112709A2 (fr) * 2003-06-13 2004-12-29 Irm Llc Inhibiteurs de cathepsine s
WO2004112709A3 (fr) * 2003-06-13 2005-04-07 Irm Llc Inhibiteurs de cathepsine s
US7173051B2 (en) 2003-06-13 2007-02-06 Irm, Llc Inhibitors of cathepsin S
JP2007502844A (ja) * 2003-08-20 2007-02-15 アイアールエム・リミテッド・ライアビリティ・カンパニー カテプシンｓの阻害剤
US7256207B2 (en) 2003-08-20 2007-08-14 Irm Llc Inhibitors of cathepsin S
US7507755B2 (en) 2003-08-20 2009-03-24 Irm Llc Inhibitors of cathepsin s
US7358373B2 (en) 2005-07-27 2008-04-15 Roche Palo Alto Llc Cathepsin K inhibitors
WO2008147228A1 (fr) * 2007-05-31 2008-12-04 Fonterra Corporate Research And Development Limited Traitement ou prévention de maladies osseuses
WO2009125861A1 (fr) * 2008-04-09 2009-10-15 帝人ファーマ株式会社 Inhibiteur de cystéine protéase
WO2009128521A1 (fr) * 2008-04-15 2009-10-22 帝人ファーマ株式会社 Inhibiteur de cystéine protéase

Also Published As

Publication number Publication date
WO2002070517A3 (fr) 2003-01-16
AU2002242500A1 (en) 2002-09-19

Similar Documents

Publication Publication Date Title
US6835727B2 (en) Cathepsin cysteine protease inhibitors
RU2695133C1 (ru) Производные оксадиазоламина в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция
US8772336B2 (en) Cathepsin cysteine protease inhibitors
RU2607045C2 (ru) Бензиламиновые производные как ингибиторы калликреина плазмы
US9006454B2 (en) Dihydroorotate dehydrogenase inhibitors
CA2691987C (fr) Agents antibacteriens
EP1372655B1 (fr) Inhibiteurs de cathepsines de la cysteine protease
TW200922556A (en) Novel cathepsin C inhibitors and their use
WO2002070517A2 (fr) Inhibiteurs de cysteine protease de type cathepsine
KR20060009933A (ko) 시아노플루오로피롤리딘 유도체
WO2012130299A1 (fr) Inhibiteurs de peptidase
CA3105352A1 (fr) Derives d'acide (s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoique et composes apparentes utilises en tant qu'inhibiteurs de caspase pour le traitement de maladies cardiovasculaires
EP1660471B1 (fr) Derives d'acide hydroxamique utilises comme inhibiteurs de metalloproteinases
CA3016086A1 (fr) Composes inhibiteurs de cyclophilines et leurs utilisations
EP3033339B1 (fr) Dérivés de la cyclopentyleamine 3-substitués
WO2015051479A1 (fr) Inhibiteurs de cystéine-protéases de type cathepsines
ES2266806T3 (es) Derivados de piridazina, su utilizacion como medicamentos y su procedimiento de preparacion.
WO2015200349A2 (fr) Inhibiteurs de l'élastase
AU2014308182A1 (en) 3-substituted cyclopentylamine derivatives
JP2011079777A (ja) システインプロテアーゼ阻害剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP